Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Phase 3 crawled date : 2021 - 09 - 09 save search
Apellis Announces Top-Line Results from Phase 3 DERBY and OAKS Studies in Geographic Atrophy (GA) and Plans to Submit NDA to FDA in the First Half of 2022
Published: 2021-09-09 (Crawled : 22:00) - biospace.com/
APLS G | $49.59 1.79% 630K
|
Health Technology
|
| O: -0.88%
H: 2.83%
C: 0.94%
fda results phase 3 topline fda ide
Icosavax Initiates Phase 1/1b Trial of VLP Vaccine Candidate Against Respiratory Syncytial Virus- Phase 1/1b clinical trial will assess the safety and immunogenicity of IVX-121 in healthy adults, including older adults -
Published: 2021-09-09 (Crawled : 15:00) - biospace.com/
ICVX | $15.31 -0.65% 9.3M
|
|
| O: -0.28%
H: 2.89%
C: -0.2%
phase 1 respiratory vaccine trial phase 2 phase 3 order
Longeveron Announces Final Results of Phase 1 Clinical Study of Lomecel-B Injection in Hypoplastic Left Heart Syndrome Patients
Published: 2021-09-09 (Crawled : 14:00) - biospace.com/
LGVN 4 d | $1.7 -6.59% 280K
|
|
| O: 3.03%
H: 6.95%
C: 4.28%
heart phase 1 injection results phase 2 phase 3 syndros lomecel-b
Sanofi provides update on Phase 3 study evaluating rilzabrutinib for the treatment of pemphigus
Published: 2021-09-09 (Crawled : 06:00) - globenewswire.com
SNY | News | $46.765 -1.94% 950K
|
Health Technology
|
| O: -1.54%
H: 0.23%
C: -0.59%
treatment phase 3
Gainers vs Losers
| 58% | 42% |
Top 10 Gainers
CSSE 4 | $0.3831 151.54% 190M
|
Consumer Services
CZOO | $11.04 121.24% 11M
|
LICN | $0.9107 62.63% 14M
|
BOF | $1.87 59.83% 100M
|
AMST | $3.18 59.0% 67M
|
Technology Services
MTC | $3.31 47.77% 7.7M
|
Technology Services
MULN | News | $3.915 43.41% 12M
|
Information
WIMI | $1.04 43.37% 17M
|
Technology Services
SKIL 4 | $8.045 40.89% 230K
|
Information
RILY | $30.01 38.17% 11M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.